Clinical trial
Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating…
NCT00335764 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00335764 |
|---|---|
| Title | Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma |
| Official title | Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor |
| Intervention type | Drug |
| Interventions | sorafenib tosylate, erlotinib hydrochloride, tipifarnib, temsirolimus |
| Enrollment | 92 |
| Start date | Apr 1, 2006 |
| Primary completion | Feb 1, 2010 |
| Completion | Sep 1, 2012 |
| First posted | Jun 12, 2006 |
| Last update posted | Jul 2, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: